Search company, investor...
Hybrid Plastics company logo

Hybrid Plastics


Unattributed VC - II | Alive

Total Raised


Last Raised

$740K | 10 yrs ago

About Hybrid Plastics

Hybrid Plastics manufactures POSS Nanostructured Chemicals, Flow Aids, Dispersion Aids and Thermoset resins. It is a new Nanotechnology based on silicon-derived building blocks that provide nanometer- scale control to improve the properties of traditional polymers. POSS nanoscopic chemical technology provides opportunities to create revolutionary material combinations through a melding of the desirable properties of ceramics and polymers at the 1 nm length scale.

Headquarters Location

55 W.L. Runnels Industrial Drive

Hattiesburg, Mississippi, 39401,

United States


Missing: Hybrid Plastics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Hybrid Plastics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Hybrid Plastics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hybrid Plastics is included in 1 Expert Collection, including Advanced Materials.


Advanced Materials

1,282 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.

Hybrid Plastics Patents

Hybrid Plastics has filed 14 patents.

The 3 most popular patent topics include:

  • Calcium compounds
  • Coagulation system
  • EC 2.4.1
patents chart

Application Date

Grant Date


Related Topics




Fluid dynamics, Polymers, Colloidal chemistry, Iris (plant), Poisonous plants


Application Date


Grant Date



Related Topics

Fluid dynamics, Polymers, Colloidal chemistry, Iris (plant), Poisonous plants



Latest Hybrid Plastics News

This Future Army Battlefield Wound Treatment Gels With Elegant Simplicity

May 16, 2021

U.S. Army photo by Spc. Brian Chaney It should come as no surprise that blood hemorrhaging is a leading cause of preventable death for Soldiers in combat. But the Army Research Laboratory (ARL) is providing technical oversight for a new kind of gel which can stop bleeding without the negative side effects that come with a tourniquet or other time-tested methods. It could be in the hands of Soldiers and Marines in as little as five years from now - a relative heartbeat by typical medical and FDA certification certification standards - thanks to its simplicity. The gel, which goes by the name of Statbond, is based on a proprietary silicon-like formulation developed by Hybrid Plastics Inc , a chemical and nanotechnology developer and manufacturer based in Hattiesburg, Mississippi. A compound called Polyhedral Oligomeric Silsesquioxane (POSS) is the central ingredient in Statbond which would be applied to a wound much in the same way you’d squeeze toothpaste out of tube. The gel that is Statbond is based on a chemical compound called POSS. Army Research Laboratory “You’d have an applicator, sort of like a syringe but with a polymer tip. You squeeze [the gel] out into the wound site. Its roughly the consistency of molasses,” says Dr. Robert Mantz, a chemistry branch chief with ARL and program manager for Statbond. MORE FOR YOU “It basically spreads into the wound and facilitates blood clotting. It doesn’t cure, it doesn’t harden, it doesn’t react with anything,” Dr Mantz adds. Such qualities are highly desirable. Treatments like wound-filling foams or polymers have been tried before but they tend to cure. By the time a wounded soldier makes it to a field hospital or operating room, such appliques need to be cleaned out of the tissue. If sticky or flaky, cleaning extends the time needed to treat a wound before surgery. “As you’re removing these, you can dislodge the clot that has formed,” Mantz explains. “They might burn some of the surrounding tissue. All you have to do with this gel is wipe it out with a gauze and anything that’s left is absorbed by the body over time.” Statbond is also appealing because it can be effective where traditional means of staunching blood flow aren’t. Tourniquets and standard dressings rely on compression to slow uncontrolled arterial bleeding, preventing critical blood loss. But parts of the body like the groin, trunk, armpit, neck and internal organs either can’t be effectively compressed or may suffer further damage from compression. Currently, there is no battlefield treatment for such bleeding because these injuries are not responsive to the compression treatments used by soldiers and medics. “You can’t put a tourniquet on around the neck, the groin or the chest,” Dr. Mantz affirms. “We put gauze and bandage on and try to wrap it up to apply some pressure without affecting a person’s ability to breathe or maintain consciousness.” Squirted into a wound and covered with a bandage, Statbond has demonstrated the ability to stop blood flow and initiate clotting in clinical studies. It does not have an antiseptic component in the interest of simplifying and speeding its certification. “We’re looking at something as simple as possible and, as we like to say, as soldier-proof as possible. They can apply this easily and not make the situation worse,” Mantz says. Simple enough to be "soldier-proof", Stratbond would be applied by a syringe-like applicator and ... [+] covered with a conventional bandage. Army Research Laboratory With funding from the Defense Health Agency/ARL, Hybrid Plastics and co-developers, the University of Mississippi Medical Center, Vanderbilt University and Ichor Sciences have begun walking Statbond up the FDA certification ladder. Testing with human-representative mammals is just getting underway and vetting of Hybrid Plastics’ production process has begun as well. So far, its progress appears to be refreshingly straightforward. “I hate to say everything looks routine without jinxing it,” Dr. Mantz quips, “but right now it looks very promising.” Hybrid Plastics is also pursuing a Statbond-like formulation for animals in veterinary applications. Moreover, the company is positioning its POSS compound for industrial coatings, personal care products, lubricants, electronic sensor and optical coatings. Statbond’s promise - in lives potentially saved and successful near-battlefield medical procedures - is not something ARL program managers often see while helping advance or sponsor basic research Dr. Mantz acknowledges. “We focus on funding basic research which usually means there’s a long timeline before that science will be implemented. Occasionally, we have the opportunity to transition something to give the soldier an edge, that’s always rewarding. Frankly it doesn’t happen that often.”

Hybrid Plastics Frequently Asked Questions (FAQ)

  • Where is Hybrid Plastics's headquarters?

    Hybrid Plastics's headquarters is located at 55 W.L. Runnels Industrial Drive, Hattiesburg.

  • What is Hybrid Plastics's latest funding round?

    Hybrid Plastics's latest funding round is Unattributed VC - II.

  • How much did Hybrid Plastics raise?

    Hybrid Plastics raised a total of $740K.

  • Who are the investors of Hybrid Plastics?

    Investors of Hybrid Plastics include Advantage Capital.

  • Who are Hybrid Plastics's competitors?

    Competitors of Hybrid Plastics include Nexeon and 4 more.

Compare Hybrid Plastics to Competitors

OneD Battery Sciences

OneD Battery Sciences is the creator of SINANODE, technology that adds more energy-dense silicon into the anodes of EV batteries. The company operates a SINANODE pilot production program to support the development of advanced electrochemical cells and the production scale-up of its industrial partners. The company is based in 2013 and is based in Palo Alto, California.

TissueTech Logo

TissueTech provides regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. AmnioGraft, AmnioGuard, and PROKERA are cryopreserved amniotic membrane grafts processed using the CRYOTEK Method to ensure that the tissue is able to deliver anti-inflammatory, anti-angiogenic, anti-scarring, and wound healing actions.

Mobius Power

Mobius Power is developing next-generation battery technology

Ecovative Design

Ecovative Design is a biomaterials company that provides sustainable alternatives to plastics and polystyrene foams for packaging, building materials, and other applications by using mushroom technology. It was founded in 2007 and is based in Green Island, New York.

Connective Orthopaedics

Connective Orthopaedics is a medical device company focused on the repair of soft tissue injuries.

Control Medical

Control Medical Technology designs, develops, and markets medical devices to help physicians, nurses, technicians, and other caregivers improve patient care. Its FDA-approved ASPIRE systems are used to remove fluids, tumors, bone, bone marrow, endometrial fluids, blood clots, tissue, and other pathology, targeting unmet clinical needs in oncology, orthopedics, spine, pain management and cardiovascular medicine.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.